Jingxin Pharmaceutical's share repurchase exceeds 5% threshold

Zhejiang Jingxin Pharmaceutical (SZSE:002020) announced that its ongoing share repurchase program has reached a significant milestone, with the company now holding 5.02% of its total share capital as of May 7, 2025. The company has been repurchasing shares through its dedicated securities account via centralized bidding. The total number of shares repurchased is 4,322.8495 million. The highest transaction price paid was CNY 14.41 per share, with the lowest at CNY 11.86 per share, for a total expenditure of CNY 55,459.09 million (excluding transaction costs). This repurchase is part of a previously announced plan to utilize company funds to repurchase shares at a price not exceeding CNY 14.8 per share, intended for equity incentives or employee stock ownership plans. The company affirmed its adherence to relevant regulations and its intention to continue the repurchase program based on market conditions.